Good Practice Statements for the treatment of nicotine dependence

The current and potential future scenario regarding consumers of new and emerging tobacco and nicotine products and their sustained addiction to nicotine is a significant global public health concern. To address this issue, it is crucial to incorporate individuals addicted to these products into the existing treatments for smoking cessation, as per the Good Practice Statements (GPS) provided by the GRADE working group 1-3 . GPS

[1]  T. Tabuchi,et al.  The Usefulness of a Smartphone App–Based Smoking Cessation Program for Conventional Cigarette Users, Heated Tobacco Product Users, and Dual Users: Retrospective Study , 2023, Journal of medical Internet research.

[2]  P. Tugwell,et al.  Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal , 2022, BMJ Evidence-Based Medicine.

[3]  P. Tugwell,et al.  A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations. , 2021, Journal of clinical epidemiology.

[4]  Michael S. Amato,et al.  Effectiveness of a Vaping Cessation Text Message Program Among Young Adult e-Cigarette Users , 2021, JAMA internal medicine.

[5]  S. McGill,et al.  Pharmacological Interventions for Vaping Cessation , 2021 .

[6]  Amanda L. Graham,et al.  A synthesis of the literature to inform vaping cessation interventions for young adults. , 2021, Addictive behaviors.

[7]  M. Sohn,et al.  Pilot Study of Electronic Nicotine Delivery Systems (ENDS) Cessation Methods , 2020, Pharmacy.

[8]  Scott E. Hadland,et al.  Through the Haze: What Clinicians Can Do to Address Youth Vaping. , 2020, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[9]  Amanda S. Eloma,et al.  Varenicline for cessation from nicotine-containing electronic cigarettes. , 2019, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[10]  G. Guyatt,et al.  Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. , 2016, Journal of clinical epidemiology.

[11]  A. Goldstein,et al.  Successful use of nicotine replacement therapy to quit e‐cigarettes: lack of treatment protocol highlights need for guidelines , 2016, Clinical case reports.

[12]  K. Vickers,et al.  Interventions for smokeless tobacco use cessation. , 2015, The Cochrane database of systematic reviews.

[13]  Brian T. O’Neill,et al.  Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation , 2005 .

[14]  L. Hulvershorn,et al.  Clinical Perspective: Treatment of adolescent e-cigarette use – limitations of existing nicotine use disorder treatment and future directions for e-cigarette use cessation , 2021 .

[15]  A. Valent.  Tobacco and Nicotine Cessation During Pregnancy , 2022 .

[16]  40026386 Return Undeliverable,et al.  Canadian Agency for Drugs and Technologies in Health , 2009 .